Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.46 |
| ▸ | FOS | P01100 | 2/20 | 0.46 |
| ▸ | JUN | P05412 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28474511 | 0.98 | MAOB (0.50) | MAOBGAAMAPTTSHRTAAR1 | |
| SCHEMBL3140338 | 0.85 | TUBB4A (0.60) | GAAMAPTTSHRLMNAMEN1 | |
| SCHEMBL423387 | 0.82 | MAPT (0.56) | GAAMAPTMAPK1LMNAGLA | |
| SCHEMBL30480119 | 0.82 | MAPT (0.56) | GAAMAPTMAPK1LMNAGLA | |
| Bromide SCHEMBL11715283 | 0.81 | MAPT (0.54) | GAAMAPTMAPK1LMNAGLA | |
| Hydrochloric Acid SCHEMBL5123360 | 0.81 | MAPT (0.54) | GAAMAPTMAPK1LMNAGLA | |
| Hydrochloric Acid SCHEMBL7102293 | 0.81 | MAPT (0.54) | GAAMAPTMAPK1LMNAGLA | |
| SCHEMBL5169379 | 0.81 | MAOB (0.47) | MAOBGAAMAPTTSHRTAAR1 | |
| SCHEMBL3661649 | 0.80 | TSHR (0.55) | MAOBGAAMAPTTSHRMAPK1 | |
| SCHEMBL12259328 | 0.79 | MAPT (0.53) | GAAMAPTTSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192666-A | Bio-based silica gel material and preparation method thereof | 广东彩汇美新材料技术有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-20120186998-A1 | Microelectrode, Microelectrode formation, and methods of utilizing microelectrodes for charaterizing properties of localized environments and substrates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | claimed |
| WO-2008039320-A1 | MICROELECTRODES, MICROELECTRODE FORMATION, AND METHODS OF UTILIZING MICROELCTRODES FOR CHARACTERIZING PROPERTIES OF LOCALIZED ENVIRONMENTS AND SUBSTRATES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-03 | — | — | WO | claimed |
| CN-120192666-A | Bio-based silica gel material and preparation method thereof | 广东彩汇美新材料技术有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-120192666-A | Bio-based silica gel material and preparation method thereof | 广东彩汇美新材料技术有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-2848617-B1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-9751882-B2 | Diaryl[A, G]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof | KINGSOUND & PARTNER (CN) | 2017-09-05 | — | — | US | disclosed |
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-21 | — | — | US | disclosed |
| EP-2848617-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-03-18 | — | — | EP | disclosed |
| EP-2585824-A2 | GENETIC RISK ANALYSIS IN REWARD DEFICIENCY SYNDROME | Kenber, LLC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120186998-A1 | Microelectrode, Microelectrode formation, and methods of utilizing microelectrodes for charaterizing properties of localized environments and substrates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20120053070-A1 | Genetic Risk Analysis In Reward Deficiency Syndrome | BLUM KENNETH (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011133949-A2 | GENETIC RISK ANALYSIS IN REWARD DEFICIENCY SYNDROME | KENBER, LLC (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2008039320-A1 | MICROELECTRODES, MICROELECTRODE FORMATION, AND METHODS OF UTILIZING MICROELCTRODES FOR CHARACTERIZING PROPERTIES OF LOCALIZED ENVIRONMENTS AND SUBSTRATES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-03 | — | — | WO | disclosed |
| US-4191765-A | 1-Aryloxy-2-hydroxy-3-aminopropanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | HTR5A, HTR1F, QDPR | MAOB 118/4885GAA 589/4885MAPT 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.